Is Thermo Fisher Scientific, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Thermo Fisher Scientific, Inc. moved from expensive to fair. The company appears fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 26, an EV to EBITDA of 18.39, and a Price to Book Value of 3.44. In comparison to peers, Abbott Laboratories has a P/E of 18.36, while Intuitive Surgical, Inc. has a significantly higher P/E of 63.32, indicating that Thermo Fisher is positioned reasonably within its industry.
In terms of recent performance, Thermo Fisher's stock has returned 2.69% over the past week, outperforming the S&P 500's return of 1.70% during the same period. However, over the past year, the company has underperformed with a return of -10.07% compared to the S&P 500's 14.08%. Overall, these metrics suggest that while Thermo Fisher is currently fairly valued, its recent stock performance indicates some challenges relative to broader market trends.